Literature DB >> 26035253

Effects of a T-type calcium channel blocker, ABT-639, on spontaneous activity in C-nociceptors in patients with painful diabetic neuropathy: a randomized controlled trial.

Jordi Serra1, W Rachel Duan, Charles Locke, Romà Solà, Wei Liu, Wolfram Nothaft.   

Abstract

T-type calcium channels are a potential novel target for treatment of neuropathic pain such as painful diabetic neuropathy. ABT-639 is a peripherally acting highly selective T-type Ca(v)3.2 calcium channel blocker that has demonstrated analgesic efficacy in preclinical models and may have the potential to reduce spontaneous fiber activity. Microneurography is a unique technique that directly assesses the function of peripheral sensory afferents and measures abnormal spontaneous activity in single peripheral nociceptive C fibers. Abnormal spontaneous activity in C-nociceptors functions as a marker for spontaneous pain, as reduction of this activity could indicate analgesic efficacy. This randomized, double-blind controlled study evaluated the effects of a single 100-mg oral dose of ABT-639, compared with placebo, on abnormal spontaneous activity in peripheral C-nociceptors, measured for the first time by microneurography in adult patients with painful diabetic neuropathy. Lidocaine was included in this study and compared with placebo. Pharmacokinetics and safety of ABT-639 were evaluated. Thirty-nine patients were randomized, and a total of 56 analyzable C-nociceptors with spontaneous activity were identified in 34 patients. There were no significant differences in C-nociceptor activities after ABT-639 treatment vs placebo. Similar findings were observed for lidocaine vs placebo. There were no clinically significant findings in the safety of ABT-639. Further research of T-type Ca(v)3.2 calcium channels as potential treatment targets for painful diabetic neuropathy is warranted. The utilization of microneurography as a means to measure abnormal activity in C-nociceptors in human clinical studies opens new possibilities for future studies of compounds targeting peripheral nerve hyperexcitability. ClinicalTrials.gov identifier: NCT01589432.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26035253     DOI: 10.1097/j.pain.0000000000000249

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  20 in total

Review 1.  Recent advances in the development of T-type calcium channel blockers for pain intervention.

Authors:  Terrance P Snutch; Gerald W Zamponi
Journal:  Br J Pharmacol       Date:  2017-07-12       Impact factor: 8.739

2.  Reducing CXCR4-mediated nociceptor hyperexcitability reverses painful diabetic neuropathy.

Authors:  Nirupa D Jayaraj; Bula J Bhattacharyya; Abdelhak A Belmadani; Dongjun Ren; Craig A Rathwell; Sandra Hackelberg; Brittany E Hopkins; Herschel R Gupta; Richard J Miller; Daniela M Menichella
Journal:  J Clin Invest       Date:  2018-04-23       Impact factor: 14.808

3.  Hyperpolarization-activated cyclic nucleotide-gated 2 (HCN2) ion channels drive pain in mouse models of diabetic neuropathy.

Authors:  Christoforos Tsantoulas; Sergio Laínez; Sara Wong; Ishita Mehta; Bruno Vilar; Peter A McNaughton
Journal:  Sci Transl Med       Date:  2017-09-27       Impact factor: 17.956

Review 4.  Voltage-dependent CaV3.2 and CaV2.2 channels in nociceptive pathways.

Authors:  Lucia Hoppanova; Lubica Lacinova
Journal:  Pflugers Arch       Date:  2022-01-18       Impact factor: 3.657

Review 5.  Cutaneous pain in disorders affecting peripheral nerves.

Authors:  Cheryl L Stucky; Alexander R Mikesell
Journal:  Neurosci Lett       Date:  2021-10-01       Impact factor: 3.046

Review 6.  Studying human nociceptors: from fundamentals to clinic.

Authors:  Steven J Middleton; Allison M Barry; Maddalena Comini; Yan Li; Pradipta R Ray; Stephanie Shiers; Andreas C Themistocleous; Megan L Uhelski; Xun Yang; Patrick M Dougherty; Theodore J Price; David L Bennett
Journal:  Brain       Date:  2021-06-22       Impact factor: 15.255

7.  A randomized double-blind, placebo-, and active-controlled study of T-type calcium channel blocker ABT-639 in patients with diabetic peripheral neuropathic pain.

Authors:  Dan Ziegler; W Rachel Duan; Guohua An; James W Thomas; Wolfram Nothaft
Journal:  Pain       Date:  2015-10       Impact factor: 7.926

8.  Methodology for self-report of rest pain (or spontaneous pain) vs evoked pain in chronic neuropathic conditions: a prospective observational pilot study.

Authors:  David He; Brian Grant; Ronald R Holden; Ian Gilron
Journal:  Pain Rep       Date:  2017-03-10

9.  Modulation of T-type Ca2+ channels by Lavender and Rosemary extracts.

Authors:  Chaymae El Alaoui; Jean Chemin; Taoufiq Fechtali; Philippe Lory
Journal:  PLoS One       Date:  2017-10-26       Impact factor: 3.240

Review 10.  Discovery and validation of biomarkers to aid the development of safe and effective pain therapeutics: challenges and opportunities.

Authors:  Karen D Davis; Nima Aghaeepour; Andrew H Ahn; Martin S Angst; David Borsook; Ashley Brenton; Michael E Burczynski; Christopher Crean; Robert Edwards; Brice Gaudilliere; Georgene W Hergenroeder; Michael J Iadarola; Smriti Iyengar; Yunyun Jiang; Jiang-Ti Kong; Sean Mackey; Carl Y Saab; Christine N Sang; Joachim Scholz; Marta Segerdahl; Irene Tracey; Christin Veasley; Jing Wang; Tor D Wager; Ajay D Wasan; Mary Ann Pelleymounter
Journal:  Nat Rev Neurol       Date:  2020-06-15       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.